About XEPLION®

What is XEPLION?

XEPLION (paliperidone palmitate) is a once monthly, long acting antipsychotic medication, approved in Europe for the treatment of schizophrenia.¹

XEPLION can help people with schizophrenia to maintain continuous treatment, control their symptoms and avoid relapse.²⁻⁶ This enables people with the condition to focus on shaping their future and enjoy a more fulfilling, well rounded life, which may include returning to work or study, independent living and social relationships.

How XEPLION works

Scientists believe that the symptoms of schizophrenia, such as hallucinations, delusions, lack of emotional response, social withdrawal/depression, apathy and a lack of drive or initiative are mainly caused by abnormalities in the activity of two particular neurotransmitters in the brain, dopamine and serotonin. XEPLION blocks dopamine and serotonin receptors to control the symptoms of schizophrenia.⁷

Efficacy

• XEPLION has been shown to have an early onset of efficacy in the treatment of schizophrenia
  - XEPLION showed significant improvements by day 8 of treatment compared to placebo as measured using the Positive and Negative Syndrome Scale (PANSS) without the need for additional oral antipsychotic medication³,⁴
  - The PANSS is a measure which healthcare professionals use to assess the symptomatic change in the severity of schizophrenia
• Treatment with XEPLION resulted in significant improvements in patients’ ability to engage in personal and social life activities, as measured using the Personal and Social Performance Scale (PSP)³,⁵
• XEPLION also showed a significant reduction in the risk of relapse compared to placebo⁵
• The reduction in symptoms and improvement in ability to engage in everyday activities observed with XEPLION were maintained in the longer term⁶

Safety profile

• XEPLION is well tolerated. The overall incidence of adverse events with XEPLION is similar to placebo.³ XEPLION is also associated with a low potential for movement disorders, weight gain and side effects related to the hormone prolactin.⁹,¹⁰

Administration

XEPLION is administered by once monthly injection by a healthcare practitioner.¹

Many people with schizophrenia have difficulty taking their medication as they should,² but even short interruptions in treatment can lead to a relapse.⁸ Long acting treatments like XEPLION mean...
that people with schizophrenia don’t need to remember to take their medication daily, therefore they may help improve adherence and reduce the risk of a relapse.\(^6\)

For more information


[www.janssen-emea.com](http://www.janssen-emea.com)

References

1. XEPLION is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, XEPLION may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed. XEPLION EU Summary of Product Characteristics June 2012


